BofA lowered the firm’s price target on Janux Therapeutics to $26 from $29 and keeps a Buy rating on the shares post the Q4 results. The analyst sees higher risk to the company’s platform value given the challenging macroenvironment and adjust med its asset value per share based on clinical development updates.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JANX: